The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     
 


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Holmberg, M. T.
Right arrow Articles by Meri, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Holmberg, M. T.
Right arrow Articles by Meri, S.
The Journal of Immunology, 2001, 167: 935-939.
Copyright © 2001 by The American Association of Immunologists

Regulation of Complement Classical Pathway by Association of C4b-Binding Protein to the Surfaces of SK-OV-3 and Caov-3 Ovarian Adenocarcinoma Cells1

Mikko T. Holmberg*, Anna M. Blom{dagger} and Seppo Meri2,*

* Department of Bacteriology and Immunology, Haartman Institute, University of Helsinki, Helsinki, Finland; and {dagger} Department of Clinical Chemistry, Lund University, University Hospital, The Wallenberg Laboratory, Malmö, Sweden

The role of fluid-phase regulators of complement is to inhibit excessive complement activation and maintain homeostasis in blood. By binding to and inactivating complement components on cell surfaces, they can also protect autologous cells from complement-mediated cytotoxicity and phagocytosis. In this study, we wanted to find out whether C4b-binding protein (C4bp), a fluid-phase regulator of the classical complement pathway, could directly bind to cell surfaces in a functionally active form. After screening several malignant cell lines, we observed that the ovarian adenocarcinoma cell lines SK-OV-3, Caov-3, and SW626 were capable of binding C4bp. Binding tests with recombinant deletion mutants suggested that the primary binding site on C4bp is located on the {alpha}-chain complement control protein 4 domain. Functional tests showed that tumor cell-bound C4bp retained its cofactor activity for factor I-mediated inactivation of C4b, thus increasing the control of classical complement pathway activation on the surfaces of these cells. These results demonstrate a novel mechanism of complement regulation on cell surfaces, particularly on those of malignant ovarian tumor cells.




This article has been cited by other articles:


Home page
Biol. Reprod.Home page
M. I. Nonaka, Y. Hishikawa, N. Moriyama, T. Koji, R. T. Ogata, A. Kudo, H. Kawakami, and M. Nonaka
Complement C4b-Binding Protein as a Novel Murine Epididymal Secretory Protein
Biol Reprod, December 1, 2003; 69(6): 1931 - 1939.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
T. Areschoug, M. Stalhammar-Carlemalm, I. Karlsson, and G. Lindahl
Streptococcal beta Protein Has Separate Binding Sites for Human Factor H and IgA-Fc
J. Biol. Chem., April 5, 2002; 277(15): 12642 - 12648.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 2001 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 2001 by The American Association of Immunologists, Inc. All rights reserved.